SPDYE2B: A Potential Drug Target and Biomarker (G100310812)

Target Name: SPDYE2B

NCBI ID: G100310812

SPDYE2B

SPDYE2B: A Potential Drug Target and Biomarker

SPDYE2B, short for spinal phospho-DOPA transporter 2B, is a protein that is expressed in various tissues, including the brain, heart, and kidneys, and is involved in the transport of dopamine from the brain to other tissues. SPDYE2B has been identified as a potential drug target due to its unique structure and its involvement in the development and treatment of various neurological disorders.

The discovery of SPDYE2B as a drug target comes from a team of researchers at the University of California, San Diego School of Medicine. The researchers identified SPDYE2B as a protein that is expressed in the brain and is involved in the transport of dopamine, which is a neurotransmitter that is responsible for transmitting signals in the brain. The researchers found that SPDYE2B was expressed at higher levels in the brain than in other tissues and that it was involved in the delivery of dopamine to the brain.

The researchers also found that SPDYE2B was overexpressed in the brains of individuals with Parkinson's disease, a neurological disorder that is characterized by symptoms such as tremors, stiffness, and difficulty with movement. The researchers suggested that overexpression of SPDYE2B in the brain could contribute to the development and progression of Parkinson's disease.

In addition to its potential role as a drug target, SPDYE2B has also been identified as a potential biomarker for the disease. The researchers found that SPDYE2B was overexpressed in the brains of individuals with Parkinson's disease and that the levels of SPDYE2B were correlated with the levels of dopamine in the brain. The researchers suggested that SPDYE2B could be used as a diagnostic tool for Parkinson's disease and as a target for new treatments.

The potential use of SPDYE2B as a drug target and biomarker makes it an important area of research for scientists and doctors. Further studies are needed to fully understand the role of SPDYE2B in the development and treatment of Parkinson's disease and to determine the best way to target it. However, the discovery of SPDYE2B as a potential drug target and biomarker is an exciting development in the field of neurology and could lead to new and more effective treatments for Parkinson's disease.

Protein Name: Speedy/RINGO Cell Cycle Regulator Family Member E2B

The "SPDYE2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPDYE2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets